Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron and Sanofi will launch Dupixent with a gross sticker price of $37,000 per year, before insurance discounts and rebates.

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

XBiotech Silent as Deadline for European Resubmission of Colon Cancer Drug Passes

XBiotech Silent as Deadline for European Resubmission of Colon Cancer Drug Passes

The XBiotech drug, Xilonix, had no effect on the size of colon cancer tumors with zero complete or partial responses reported in the phase III study.